271 related articles for article (PubMed ID: 27064689)
1. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.
Vasu S; Wu H; Satoskar A; Puto M; Roddy J; Blum W; Klisovic R; Andritsos L; Hofmeister C; Benson DM; Efebera Y; Jaglowski S; Penza S; Cohen D; Devine S; Cataland S
Bone Marrow Transplant; 2016 Sep; 51(9):1241-4. PubMed ID: 27064689
[No Abstract] [Full Text] [Related]
2. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
Rudoni J; Jan A; Hosing C; Aung F; Yeh J
Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
[TBL] [Abstract][Full Text] [Related]
3. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
de Fontbrune FS; Galambrun C; Sirvent A; Huynh A; Faguer S; Nguyen S; Bay JO; Neven B; Moussi J; Simon L; Xhaard A; Resche-Riggon M; O'Meara A; Fremeaux-Bacchi V; Veyradier A; Socié G; Coppo P; de Latour RP
Transplantation; 2015 Sep; 99(9):1953-9. PubMed ID: 25651309
[TBL] [Abstract][Full Text] [Related]
4. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
5. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy.
Peffault de Latour R; Xhaard A; Fremeaux-Bacchi V; Coppo P; Fischer AM; Helley D; Socié G
Br J Haematol; 2013 Apr; 161(2):279-80. PubMed ID: 23294015
[No Abstract] [Full Text] [Related]
6. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.
Román E; Mendizábal S; Jarque I; de la Rubia J; Sempere A; Morales E; Praga M; Ávila A; Górriz JL
Nefrologia; 2017; 37(5):478-491. PubMed ID: 28946961
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
8. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
Alhomoud M; Williams A; Magro C; Van Besien K; Vesole DH; Laurence J
Leuk Lymphoma; 2022 Feb; 63(2):473-477. PubMed ID: 34668824
[No Abstract] [Full Text] [Related]
9. Eculizumab therapy.
Cataland SR
Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
[No Abstract] [Full Text] [Related]
10. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease.
Bhunia N; Abu-Arja R; Bajwa RPS; Auletta JJ; Rangarajan HG
Pediatr Blood Cancer; 2019 Oct; 66(10):e27912. PubMed ID: 31264793
[TBL] [Abstract][Full Text] [Related]
12. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?
Dhakal P; Bhatt VR
Bone Marrow Transplant; 2017 Mar; 52(3):352-356. PubMed ID: 27775697
[TBL] [Abstract][Full Text] [Related]
13. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
Jan AS; Hosing C; Aung F; Yeh J
Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
[TBL] [Abstract][Full Text] [Related]
14. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
16. Use of Eculizumab in Thrombotic Microangiopathy Associated with Hematopoietic Stem Cell Transplantation.
Demircioglu S; Dogan A; Demir C
J Coll Physicians Surg Pak; 2021 Nov; 31(11):1359-1361. PubMed ID: 34689499
[TBL] [Abstract][Full Text] [Related]
17. Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus.
Alhomoud M; Scordo M; Perales MA
Bone Marrow Transplant; 2024 Jun; 59(6):904-906. PubMed ID: 38467748
[No Abstract] [Full Text] [Related]
18. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy.
Bohl SR; Kuchenbauer F; von Harsdorf S; Kloevekorn N; Schönsteiner SS; Rouhi A; Schwarzwälder P; Döhner H; Bunjes D; Bommer M
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2172-2177. PubMed ID: 28860002
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
20. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
